Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion-Reference-Cited by-同舟云学术

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

Published:2012-04-23 Issue:9 Volume:32 Page:1110-1120
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Wei S,Chen X,McGraw K,Zhang L,Komrokji R,Clark J,Caceres G,Billingsley D,Sokol L,Lancet J,Fortenbery N,Zhou J,Eksioglu E A,Sallman D,Wang H,Epling-Burnette P K,Djeu J,Sekeres M,Maciejewski J P,List A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2012139.pdf

Reference48 articles.

1. Nimer SD Myelodysplastic syndromes. Blood, 2008 111: 4841–4851.

2. Look AT Molecular Pathogenesis of MDS. Hematology Am Soc Hematol Educ Program, 2005. 156–160.

3. List A Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes. Clin Lymphoma Myeloma, 2009 9(Suppl 3): S302–S304.

4. Ebert BL Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia, 2009 23: 1252–1256.

5. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature, 2008 451: 335–339.

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial;The Lancet Haematology;2024-09

2. Targeted protein degradation: from mechanisms to clinic;Nature Reviews Molecular Cell Biology;2024-04-29

3. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications;European Journal of Haematology;2024-01-31

4. Myelodysplastic Syndrome;Comprehensive Hematology and Stem Cell Research;2024

5. Targeting cereblon in hematologic malignancies;Blood Reviews;2023-01